Sun Pharma, AstraZeneca Pharma ink pact for Sodium Zirconium Cyclosilicate in India

18 Nov 2025 Evaluate

Sun Pharmaceutical Industries and AstraZeneca Pharma India have entered into a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India.

Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma whereas Sun Pharma will promote and distribute the therapy as Gimliand. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule. Building upon AstraZeneca’s ambition to advance science, transform care and help manage life threatening conditions like Hyperkalaemia, this strategic step is a significant move in improving the management of Hyperkalaemia in India; promising enhanced availability to a crucial treatment and ultimately contributing to better patient outcomes nationwide. 

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.


Sun Pharma Inds. Share Price

1807.80 -10.80 (-0.59%)
05-Dec-2025 13:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.80
Dr. Reddys Lab 1277.40
Cipla 1526.95
Zydus Lifesciences 934.00
Lupin 2102.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×